Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
Lan-Fang Li,Ran Qi,Tian-Tian Wei,Lei Feng,Xin Zhang,Qiao Liu
DOI: https://doi.org/10.2147/rmhp.s451846
2024-04-12
Risk Management and Healthcare Policy
Abstract:Lan-Fang Li, 1 Ran Qi, 1 Tian-Tian Wei, 1 Lei Feng, 1 Xin Zhang, 1 Qiao Liu 2 1 Department of Clinical Pharmacy, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272029, People's Republic of China; 2 Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, People's Republic of China Correspondence: Qiao Liu, Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, People's Republic of China, Email Purpose: The IPSOS study provided evidence supporting the efficacy and tolerability of first-line atezolizumab compared to single-agent chemotherapy for non-small-cell lung cancer (NSCLC) patients ineligible for treatment with a platinum-containing regimen. This study aimed to assess the cost-effectiveness of atezolizumab specifically in this population, considering the perspective of the Chinese healthcare system. Patients and Methods: In this analysis, a three-state Markov model was utilized. The survival data were derived from the IPSOS clinical trial. Direct medical costs and utility values were collected from national authoritative database and published literature. The primary outcomes were costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (ICER). To ensure the robustness of our model, both one-way and probabilistic sensitivity analyses were conducted. Results: Atezolizumab monotherapy led to an increase in costs of &dollar4139.23 compared to single-agent chemotherapy. Additionally, it resulted in a gain of 0.14 QALYs, leading to an ICER of &dollar29,365.79 per QALY, which was below the willingness-to-pay threshold of &dollar36,066 per QALY used in the model. One-way sensitivity analyses revealed cost of atezolizumab and utility of progressive disease (PD) as major influencing factors for ICER. Furthermore, probabilistic sensitivity analyses confirmed our base-case results. Conclusion: From the perspective of the Chinese healthcare system, atezolizumab emerges as a cost-effective choice for the first-line treatment of NSCLC patients ineligible for platinum-based chemotherapy. Keywords: atezolizumab, cost-effectiveness, NSCLC, IPSOS The Global Burden of Disease Study has highlighted the significant impact of lung cancer as a leading contributor to the burden of non-communicable diseases worldwide. 1,2 In terms of both incidence and mortality, lung cancer takes precedence among all types of cancers, accounting for approximately 22% of cancer-related deaths in China. 3–6 Non-small cell lung cancer (NSCLC) represents the majority, ranging 85% to 90%, 7,8 of all lung cancers cases, with nearly 60% of NSCLC patient already diagnosed at an advanced stages. 9–11 According to the Chinese Society of Clinical Oncology guidelines for NSCLC (2023 edition), platinum-based chemotherapy doublets remain the primary treatment strategy for advanced NSCLC patients who not possess epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase-positive (ALK) mutations. 12 The guideline recommends this approach as the first-line option for patients with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0–1 (Level I), while it may be considered as a secondary choice (Level II) for individuals with an ECOG PS score of 2. Unfortunately, for NSCLC patients who are ineligible for platinum-containing regimens, the available treatment options are quite limited. In recent years, cancer immunotherapy, particularly with atezolizumab targeting PD-L1, has revolutionized treatment options for advanced NSCLC lacking driver mutations. 13,14 Atezolizumab's approval by the National Medical products Administation for first or second-line NSCLC treatment underscores its remarkable clinical efficacy. 15 Notably, a Phase 3 study (IPSOS) compared atezolizumab monotherapy to standard single-agent chemotherapy (gemcitabine or vinorelsbine) in the first-line treatment of NSCLC patients ineligible for platinum-containing regimens, revealing improved overall survival (median OS 10.3 months vs 9.2 months; stratified hazard ratio 0.78 [0.63–0.97], p=0.028) and a favorable safety profile for atezolizumab. 16 The study categorized patients based on PD-L1 expression levels into four tiers (TC <1%, TC ≥1%, TC 1–49%, and TC ≥50%), with varying percentages across these levels for both atezolizumab monotherapy and single-agent chemotherapy recipients. Notably, PD-L1 expression was not restricted by the nadir criteria of the IPSOS trial. Atezolizumab offers significant clinical advantages but comes with a high -Abstract Truncated-
health care sciences & services,health policy & services